Patents by Inventor Jon Amund Eriksen

Jon Amund Eriksen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10596239
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 24, 2020
    Assignee: Targovax ASA
    Inventor: Jon Amund Eriksen
  • Publication number: 20190374628
    Abstract: There is disclosed a peptide suitable for eliciting an immune response. The peptide corresponds to a fragment of the RAS protein, and comprises a region of 8 amino acids which includes a mutated position of the RAS protein. Said region has at least 6 amino acid residues, other than the mutated position, which are identical to the corresponding region of the RAS protein. The peptide has a point mutation at the amino acid corresponding to the mutated position, and the mutated position is position 146 or 117 of the RAS protein.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 12, 2019
    Inventor: Jon Amund Eriksen
  • Patent number: 10456457
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: October 29, 2019
    Assignee: TARGOVAX ASA
    Inventor: Jon Amund Eriksen
  • Patent number: 10335473
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 2, 2019
    Assignee: TARGOVAX ASA
    Inventor: Jon Amund Eriksen
  • Publication number: 20180021419
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 25, 2018
    Inventor: Jon Amund Eriksen
  • Publication number: 20170326218
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 16, 2017
    Inventor: Jon Amund Eriksen
  • Patent number: 9775892
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: October 3, 2017
    Assignee: TARGOVAX ASA
    Inventor: Jon Amund Eriksen
  • Patent number: 9757439
    Abstract: There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 12, 2017
    Assignee: TARGOVAX ASA
    Inventors: Jon Amund Eriksen, Gustav Gaudernack
  • Publication number: 20170189515
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 6, 2017
    Inventor: Jon Amund Eriksen
  • Publication number: 20170065694
    Abstract: There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.
    Type: Application
    Filed: May 5, 2015
    Publication date: March 9, 2017
    Inventors: Jon Amund Eriksen, Gustav Gaudernack
  • Publication number: 20160331820
    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
    Type: Application
    Filed: December 9, 2014
    Publication date: November 17, 2016
    Inventor: Jon Amund ERIKSEN
  • Publication number: 20160176923
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 9241968
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: January 26, 2016
    Assignee: Lytix Biopharma AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 8614177
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: December 24, 2013
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Publication number: 20120269858
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 25, 2012
    Applicant: GEMVAX AS
    Inventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
  • Patent number: 8193326
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 5, 2012
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Publication number: 20110318364
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: September 11, 2009
    Publication date: December 29, 2011
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Publication number: 20110105721
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 5, 2011
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Patent number: 7863244
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: January 4, 2011
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Patent number: 7794723
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: September 14, 2010
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen